ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
November 26 2018 - 4:08PM
Business Wire
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system (CNS) disorders, today announced that it intends to
offer and sell, in an underwritten public offering and subject to
market and other conditions, $200,000,000 of its common stock.
There can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs
& Co. LLC are acting as the joint book-running managers for the
offering. ACADIA intends to grant the underwriters a 30-day option
to purchase up to an additional $30,000,000 of its common
stock.
The shares of common stock described above are being offered by
ACADIA pursuant to a shelf registration statement filed by ACADIA
with the Securities and Exchange Commission (SEC) that became
automatically effective on November 26, 2018. A preliminary
prospectus supplement related to the offering will be filed with
the SEC and will be available on the SEC’s website located at
http://www.sec.gov. Copies of the preliminary prospectus supplement
and the accompanying prospectus related to this offering, when
available, may be obtained from BofA Merrill Lynch, NC1-004-03-43,
200 North College Street, 3rd Floor, Charlotte, NC 28255-0001,
Attn: Prospectus Department, Email:
dg.prospectus_requests@baml.com, or from J.P. Morgan Securities
LLC, Attention: Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by
email to: prospectus-eq_fi@jpmchase.com, or from Goldman Sachs
& Co. LLC, Attention: Prospectus Department, 200 West Street,
New York, NY 10282, or by telephone at (866) 471-2526, or by email
to: prospectus-ny@nyemail.gs.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About ACADIA PharmaceuticalsACADIA is a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system disorders. ACADIA has developed and is
commercializing the first and only medicine approved for the
treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis. In addition, ACADIA has ongoing
clinical development efforts in additional areas with significant
unmet need, including dementia-related psychosis, schizophrenia
inadequate response, schizophrenia-negative symptoms, major
depressive disorder, and Rett syndrome.
Forward-Looking StatementsStatements in this press release that
are not strictly historical in nature are forward-looking
statements. These statements include but are not limited to
statements related to the proposed offering of common stock by
ACADIA. These statements are only predictions based on current
information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from
those projected in any of such statements due to various factors,
including market risks and uncertainties and the satisfaction of
customary closing conditions for an offering of securities. For a
discussion of these and other factors, please refer to ACADIA’s
annual report on Form 10-K for the year ended December 31, 2017 as
well as ACADIA’s subsequent filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181126005734/en/
Investor Contact:ACADIA Pharmaceuticals Inc.Elena Ridloff,
CFA(858) 558-2871ir@acadia-pharm.com
Media Contact:ACADIA Pharmaceuticals Inc.Maurissa Messier(858)
768-6068media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024